Payment overview · 2025
General Payments
$271.42
14 reported records · 7 companies
Healthcare provider profile · identity verified
Peter Nicholas Copsis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MATTHEWS, NC · NPI 1417979485
Verified facts
What the public records show
CMS Open Payments records show Peter Nicholas Copsis, MD received $271.42 in general payments during 2025 across 14 reported records.
Abbott Laboratories accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $62.48 | 23.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.70 | 22.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.26 | 21.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.01 | 12.5% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.70 | 8.0% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.03 | 6.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.24 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.42 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.70 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $60.70 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 867 | 245 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 695 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 540 | 157 |
| Lisinopril | Lisinopril | 523 | 149 |
| Losartan Potassium | Losartan Potassium | 404 | 107 |
| Omeprazole | Omeprazole | 349 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 72 |
| Metformin Hcl Er | Metformin Hcl | 270 | 81 |
| Metformin Hcl | Metformin Hcl | 264 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 80 |
| Simvastatin | Simvastatin | 259 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 81 |
| Trazodone Hcl | Trazodone Hcl | 230 | 63 |
| Alprazolam | Alprazolam | 223 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 67 |
| Gabapentin | Gabapentin | 203 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 54 |
| Sertraline Hcl | Sertraline Hcl | 173 | 49 |
| Famotidine | Famotidine | 172 | 47 |
| Ozempic | Semaglutide | 166 | 23 |
| Eliquis | Apixaban | 160 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 43 |
| Allopurinol | Allopurinol | 120 | 29 |
| Tramadol Hcl | Tramadol Hcl | 118 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 28 |
| Jardiance | Empagliflozin | 109 | 24 |
| Alendronate Sodium | Alendronate Sodium | 106 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 25 |
| Meloxicam | Meloxicam | 98 | 25 |
| Ezetimibe | Ezetimibe | 94 | 33 |
| Carvedilol | Carvedilol | 93 | 34 |
| Montelukast Sodium | Montelukast Sodium | 91 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 89 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 25 |
| Furosemide | Furosemide | 83 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 19 |
| Potassium Chloride | Potassium Chloride | 80 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 20 |
| Ramipril | Ramipril | 77 | 23 |
| Clonazepam | Clonazepam | 75 | 11 |
| Mounjaro | Tirzepatide | 71 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 18 |
| Mirtazapine | Mirtazapine | 69 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Prednisone | Prednisone | 67 | 46 |
| Lorazepam | Lorazepam | 65 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Pregabalin | Pregabalin | 64 | 11 |
| Bupropion Xl | Bupropion Hcl | 61 | 15 |
| Warfarin Sodium | Warfarin Sodium | 59 | 13 |
| Atenolol | Atenolol | 55 | 15 |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Finasteride | Finasteride | 49 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 46 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 38 |
| Benazepril Hcl | Benazepril Hcl | 43 | 12 |
| Celecoxib | Celecoxib | 41 | 14 |
| Azelastine Hcl | Azelastine Hcl | 39 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 12 |
| Spironolactone | Spironolactone | 37 | 12 |
| Cefuroxime | Cefuroxime Axetil | 36 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Estradiol | Estradiol | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 12 |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Carbidopa | Carbidopa | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.42 · 14 records | Abbott Laboratories | APTIMA, AREXVY, FREESTYLE LIBRE 3, ImmunoCAP, JARDIANCE, KRYSTEXXA, Ozempic, Rybelsus, SHINGRIX, THINPREP 2000 PROCESSOR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error